Funding and Investments

Jan 01, 2009
BioPharm International
By BioPharm International Editors
Small biotechs were forced to restructure and downsize.
Dec 01, 2008
BioPharm International
By BioPharm International Editors
The meltdown in the financial markets represents a sea change in the world of financing that will continue to affect the flow of much needed capital into the sector for the foreseeable future.
Oct 01, 2008
BioPharm International
By BioPharm International Editors
The biotech industry's year-to-date report card contains good grades despite the turbulent economic climate.
Jun 10, 2008
By BioPharm International Editors
Health and Human Services Secretary Mike Leavitt has announced that his agency is amending its budget request for FY 2009 to include an additional $275 million for the FDA.
Jun 01, 2008
BioPharm International
By BioPharm International Editors
Following the market crisis of the first quarter of 2008, biotech IPOs and financing are down, but partnering continues, and mergers and acquisitions (M&As) remain hot.
Mar 01, 2008
BioPharm International
By BioPharm International Editors
Despite the rising fears about a slowing economy, the biotech industry will continue to maintain its momentum this year.
Nov 01, 2007
BioPharm International
By BioPharm International Editors
The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008
Feb 01, 2006
BioPharm International
By BioPharm International Editors
Like a snowball rolling down Mt. Everest, stem- cell research was gaining momentum, not only in political and medical arenas, but on Wall Street, too.
Dec 15, 2005
BioPharm International
By BioPharm International Editors
Venture capital activity in Ireland grew 25.7% in the first half of 2005 compared with the same period in 2004. New life-sciences venture capital funds have been established and existing firms have ramped up their activity in the sector.
Oct 01, 2005
BioPharm International
By BioPharm International Editors
The ripple effects of 9/11 are still being felt, creating changes among individuals, businesses, and government organizations. The biotech community is no different; companies are taking a new look at the way they do business and shifting their focuses in response to new opportunities presented by federal preparedness programs. In 2004, President Bush signed "Project BioShield," a bill that made $5.6 billion in federal funds available over a 10-year period to develop countermeasures against chemical, biological, radiological, or nuclear attack. An additional $2.5 billion was added to the initiative in 2005. Numerous grants and contracts have already been awarded to companies developing innovative prophylactic measures, treatments, and diagnostic tools to be used in the event of a biological attack.
native1_300x100
lorem ipsum